Avadel Pharmaceuticals Issues 2018 Corporate Outlook
Avadel Pharmaceuticals plc - Ordinary Share (AVDL)
Last avadel pharmaceuticals plc - ordinary share earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
avadel.com
Company Research
Source: GlobeNewswire
Commercial launch for Noctiva™ on target for second quarter 2018 NDA filing for FT218 expected by year-end 2018 Total revenues expected to range from $110 - 130 million DUBLIN, Ireland, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), “Avadel” or “the Company,” today announced its 2018 corporate objectives and financial expectations, including the commercial launch of Noctiva™ and the anticipated filing of a New Drug Application (NDA) for both FT218, a once-nightly formulation of sodium oxybate using Micropump®, and its fourth Unapproved Marketed Drug (UMD) product, AV001. For 2018, the Company has set forth the following expectations: Implement a full-scale commercial launch for Noctiva during the second quarterFile the NDA for FT218 by the end of 2018File the NDA for AV001, its fourth UMD product Maintain market leading position across its portfolio of hospital products and improve the effectiveness and efficiency of its pediatric operationsEnhance
Show less
Read more
Impact Snapshot
Event Time:
AVDL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVDL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVDL alerts
High impacting Avadel Pharmaceuticals plc - Ordinary Share news events
Weekly update
A roundup of the hottest topics
AVDL
News
- Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Avadel Pharmaceuticals plc (NASDAQ: AVDL) had its price target raised by analysts at HC Wainwright from $25.00 to $27.00. They now have a "buy" rating on the stock.MarketBeat
- Avadel Pharmaceuticals plc (NASDAQ: AVDL) had its price target raised by analysts at Craig Hallum from $22.00 to $23.00. They now have a "buy" rating on the stock.MarketBeat
- Avadel Pharmaceuticals plc (NASDAQ: AVDL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.MarketBeat
- Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
AVDL
Earnings
- 5/8/24 - Miss
AVDL
Sec Filings
- 5/8/24 - Form 8-K
- 5/8/24 - Form 424B5
- 5/8/24 - Form 10-Q
- AVDL's page on the SEC website